OPPORTUNITY TO MEET THE TREATMENT NEEDS OF
CANCER PATIENTS WITH LIMITED TREATMENT CHOICES

Every year, more than a million and a half people are diagnosed with cancer in the US, and almost 1,700 people die from this disease per day. Though the cancer survival rate as a whole has increased over the last decades, progress in therapeutic approaches has been incredibly variable, and for certain types of cancers (lung, colorectal, pancreatic), advances have been incrementally modest and unsatisfactory, or not yet developed. Bantam is committed to developing therapeutics to address these unmet needs of cancer patients.

DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

National Cancer Institute estimates 74,680 new cases of non-Hodgkin Lymphoma (NHL) in 2018. DLBCL is an aggressive sub-type of NHL.

BANTAM & DLBCL

Bantam’s lead compounds induce prolonged tumor regression and remission in DLBCL and present potential new therapeutics for relapsed and/or refractory lymphomas.

KRAS MUTANT CANCERS

The American Cancer Society estimates that 430,000 people will be diagnosed with some form of KRAS mutated cancer (colorectal, lung or pancreatic) in 2018.

BANTAM & KRAS

Pre-clinical in vitro & in vivo studies demonstrate that select solid KRAS mutated cancers respond to Bantam’s compounds.

.

DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common form of non-Hodgkin’s lymphoma and the current standard of care with chemo-immunotherapy R-CHOP) provides durable remission for only 50% of patients. Bantam’s lead candidates induce apoptosis in a wide array of DLBCL cell lines including ABC and GCB subtypes and those characterized by Myc and Bcl-2 genomic alterations (“double-hit” lymphomas).

Bantam’s compounds offer a new potential therapeutic approach that will expand the treatment options available for relapsed and refractory DLBCL; a market opportunity that exceeds $1 billion annually.

KRAS MUTATED SOLID TUMORS

Based on pre-clinical in vitro and in vivo data, Bantam compounds successfully inhibit the growth of select KRAS mutated solid tumors.  KRAS is a frequent “driver” mutation of three of the four most lethal cancers: colorectal, lung adenocarcinoma, and pancreatic adenocarcinoma. The KRAS oncology market represents a substantial unmet need for cancer patients as effective therapies targeting KRAS have yet to be developed. These cancers collectively encompass a $9 billion annual market potential.